Agomelatine Applications in Major Depressive Disorders

Agomelatine is a novel antidepressant characterised by dual pharmacological actions: melatonergic receptor agonism at MT₁ and MT₂ receptors and antagonism at the serotonin 5-HT₂C receptor. Its unique profile facilitates the resynchronisation of disrupted circadian rhythms, improvement of sleep architecture and enhancement of monoaminergic transmission in frontal cortical areas. Clinically, agomelatine has been investigated as monotherapy and as an adjunct to standard selective serotonin reuptake inhibitors (SSRIs) or serotonin–noradrenaline reuptake inhibitors (SNRIs) in patients with major depressive disorder (MDD), with evidence for favourable tolerability and a low incidence of sexual and weight‐related side-effects. Preclinical models have demonstrated neuroprotective effects, including attenuation of stress-induced neuroinflammation, rescue of hippocampal neurogenesis and reversal of synaptic and epigenetic alterations. Despite variable outcomes in augmentation trials, agomelatine’s chronobiotic and neurotrophic properties underpin its role in addressing residual symptoms and circadian disturbances often refractory to conventional antidepressants.

Research from Nature Portfolio

Recent studies in rodent models of chronic social defeat stress have shown that agomelatine prevents episodic memory deficits and restores hippocampal expression of synaptic plasticity markers and epigenetic enzymes, implicating modulation of BDNF signalling and chromatin remodelling in its cognitive benefits. A foundational medicinal chemistry effort employed scaffold-hopping strategies to generate novel 3,4-dihydroisoquinoline derivatives inspired by agomelatine, identifying candidates that not only engage melatonergic and 5-HT₂C targets but also display enhanced neuroprotective and behavioural antidepressant-like effects in vivo.

Agomelatine Applications in Major Depressive Disorders publication trend

The graph below shows the total number of articles in agomelatine applications in major depressive disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Melatonergic receptor agonist: A compound that activates MT₁ and MT₂ receptors to regulate circadian rhythms and sleep–wake cycles.

5-HT₂C receptor antagonist: A substance that blocks the serotonin 2C receptor, enhancing noradrenaline and dopamine release in the frontal cortex.

Neuroinflammation: Activation of glial cells and release of pro-inflammatory cytokines that can contribute to neuronal dysfunction in depression.

Synaptic plasticity: The capacity of synapses to strengthen or weaken over time, underlying learning, memory and mood regulation.

Epigenetic remodelling: Modifications to chromatin structure that alter gene expression without changing DNA sequence, influencing neuronal resilience.

Chronobiotic: A treatment that realigns or stabilises biological rhythms to mitigate mood and sleep disturbances.

References

1. Agomelatine as adjunctive therapy with SSRIs or SNRIs for major depressive disorder: a multicentre, double-blind, randomized, placebo-controlled trial. BMC Medicine (2025).
2. Agomelatine rescues lipopolysaccharide-induced neural injury and depression-like behaviors via suppression of the Gαi-2-PKA-ASK1 signaling pathway. Journal of Neuroinflammation (2022).
3. Effect of agomelatine on memory deficits and hippocampal gene expression induced by chronic social defeat stress in mice. Scientific Reports (2017).
4. Scaffold Hopping Toward Agomelatine: Novel 3, 4-Dihydroisoquinoline Compounds as Potential Antidepressant Agents. Scientific Reports (2016).
5. Reduced neuroinflammation and enhanced neurogenesis following chronic agomelatine treatment in rats undergoing chronic constant light. Neuropharmacology (2021).